Last reviewed · How we verify

Dexmedetomidine for sedation — Competitive Intelligence Brief

Dexmedetomidine for sedation (Dexmedetomidine for sedation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Sedation.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine for sedation (Dexmedetomidine for sedation) — Southeast University, China. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation and analgesia by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dexmedetomidine for sedation TARGET Dexmedetomidine for sedation Southeast University, China marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Group D : Dexmedetomidine + propofol group Group D : Dexmedetomidine + propofol group Seoul National University Hospital marketed Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist) Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Combigan Ophthalmic Solutiom Combigan Ophthalmic Solutiom Genovate Biotechnology Co., Ltd., marketed Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist Alpha-2 adrenergic receptors and beta-adrenergic receptors
Escitalopram+Mirtazapine Escitalopram+Mirtazapine Ministry of Health & Welfare, Korea marketed Antidepressant combination (SSRI + NaSSA) Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
Dexmedetomidine 0.5 microgram/kg Dexmedetomidine 0.5 microgram/kg Sindh Institute of Urology and Transplantation marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Pregabalin and dexmedetomidine Pregabalin and dexmedetomidine Wonkwang University Hospital marketed Combination analgesic/sedative (gabapentinoid + alpha-2 agonist) Alpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine)
Clonidine Pill Clonidine Pill Weill Medical College of Cornell University marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

  1. Allergan · 3 drugs in this class
  2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
  3. National Cancer Institute, Egypt · 2 drugs in this class
  4. The University of Hong Kong · 2 drugs in this class
  5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
  6. Fayoum University Hospital · 1 drug in this class
  7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
  8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
  9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  10. KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine for sedation — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-for-sedation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: